Jan Moritz Middeke

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8736704/publications.pdf

Version: 2024-02-01

31	802	840776 11	677142 22
papers	citations	h-index	g-index

32	32	32	1035
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease. New England Journal of Medicine, 2021, 385, 228-238.	27.0	209
2	Adoptive transfer of allogeneic regulatory T cells into patients with chronic graft-versus-host disease. Cytotherapy, 2015, 17, 473-486.	0.7	149
3	TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML. Blood Advances, 2020, 4, 5011-5024.	5.2	85
4	Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood, 2021, 137, 3145-3148.	1.4	70
5	Engrafting human regulatory T cells with a flexible modular chimeric antigen receptor technology. Journal of Autoimmunity, 2018, 90, 116-131.	6.5	64
6	Application of machine learning in the management of acute myeloid leukemia: current practice and future prospects. Blood Advances, 2020, 4, 6077-6085.	5.2	40
7	The prevalence of extramedullary acute myeloid leukemia detected by ¹⁸FDG-PET/CT: final results from the prospective PETAML trial. Haematologica, 2020, 105, 1552-1558.	3.5	31
8	Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears. Leukemia, 2022, 36, 111-118.	7.2	31
9	Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemia. Blood Cancer Journal, 2021, 11, 164.	6.2	29
10	Differential impact of IDH1/2 mutational subclasses on outcome in adult AML: results from a large multicenter study. Blood Advances, 2022, 6, 1394-1405.	5.2	17
11	Deep learning identifies Acute Promyelocytic Leukemia in bone marrow smears. BMC Cancer, 2022, 22, 201.	2.6	14
12	Allogeneic stem cell transplantation for the treatment of refractory scleromyxedema. Translational Research, 2015, 165, 321-324.	5.0	13
13	Deep sequencing in CD34+ cells from peripheral blood enablesÂsensitive detection of measurable residual disease in AML. Blood Advances, 2022, 6, 3294-3303.	5.2	11
14	Pilot Study on Mass Spectrometryâ€“Based Analysis of the Proteome of CD34+CD123+ Progenitor Cells for the Identification of Potential Targets for Immunotherapy in Acute Myeloid Leukemia. Proteomes, 2018, 6, 11.	3.5	10
15	Clostridium Difficile infections in patients with AML or MDS undergoing allogeneic hematopoietic stem cell transplantation identify high risk for adverse outcome. Bone Marrow Transplantation, 2020, 55, 367-375.	2.4	10
16	Tafasitamab combined with idelalisib or venetoclax in patients with CLL previously treated with a BTK inhibitor. Leukemia and Lymphoma, 2021, 62, 3440-3451.	1.3	6
17	Use of rasburicase in a pregnant woman with acute lymphoblastic leukaemia and imminent tumour lysis syndrome. Annals of Hematology, 2014, 93, 531-532.	1.8	5
18	Allogeneic hematopoietic cell transplantation for patients with TP53 mutant or deleted chronic lymphocytic leukemia: Results of a prospective observational study. Bone Marrow Transplantation, 2021, 56, 692-695.	2.4	3

#	Article	IF	Citations
19	Macroscopic, histologic, and clinical assessment of acute graft-versus-host disease of the upper gastrointestinal tract within 6 weeks after allogeneic hematopoietic cell transplantation. Experimental Hematology, 2022, 108, 36-45.	0.4	2
20	Systemic Iron Overload in Patients Undergoing Allogeneic Stem Cell Transplantation â€“ a Magnetic Resonance Imaging Based Study in 81 AML and MDS Patients. Blood, 2011, 118, 489-489.	1.4	1
21	Karyotypic Complexity In Acute Myeloid Leukemia In The Context Of Adverse Prognosis. Blood, 2013, 122, 489-489.	1.4	1
22	Long-Term Mixed Chimerism After Ex Vivo/In Vivo T Cell-Depleted Allogeneic Hematopoietic Cell Transplantation in Patients With Myeloid Neoplasms. Frontiers in Oncology, 2021, 11, 776946.	2.8	1
23	Comparing the Value of Serum Ferritin, Transfusion History and Magnetic Resonance Imaging for the Prediction of Iron Overload In MDS and AML Patients Undergoing Allogeneic Stem Cell Transplantation.. Blood, 2010, 116, 3493-3493.	1.4	0
24	Appearance of Mature 6-Sulfo LacNAc+ Dendritic Cells In Early and Late Engraftment After Allogeneic Stem Cell Transplantation.. Blood, 2010, 116, 3720-3720.	1.4	0
25	Monosomal Karyotype Predicts Survival In Patients with High Risk AML Undergoing Allogeneic Stem Cell Transplantation. Blood, 2010, 116, 2748-2748.	1.4	0
26	Reconstitution of IL-17-Producing T Helper Cells After Allogeneic Hematopoietic Cell Transplantation. Blood, 2012, 120, 4167-4167.	1.4	0
27	Outcome Of Patients With Abnl(17p) Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 303-303.	1.4	0
28	TP53 Mutations In Patients With High-Risk Acute Myeloid Leukemia Treated With Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2013, 122, 711-711.	1.4	0
29	Influence Of Steroid Exposure On CMV Specific T Cells Following Allogeneic Stem Cell Transplantation. Blood, 2013, 122, 5488-5488.	1.4	0
30	Clofarabine Salvage Therapy Prior To Allogeneic Hematopoietic Stem Cell Transplantation In Patients With Relapsed Or Refractory AML â€“ Results Of The Bridge Trial â€“. Blood, 2013, 122, 304-304.	1.4	0
31	Analysis of Molecular Predictors of Response to 5-Azacitine Treatment in AML and MDS Patients Preemptively Treated for Molecular Relapse of Disease. Blood, 2014, 124, 2384-2384.	1.4	0